Clinical Trial Detail

NCT ID NCT03995017
Title Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Anwaar Saeed
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Ramucirumab + Rucaparib

Nivolumab + Ramucirumab + Rucaparib

Age Groups: adult senior

No variant requirements are available.